Related Experiment Video
Updated: Jul 20, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Pheochromocytoma/paraganglioma-associated cardiomyopathy
Alicja Szatko1,2, Piotr Glinicki1,2, Małgorzata Gietka-Czernel1
1Department of Endocrinology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Pheochromocytoma/paraganglioma (PPGL) can cause serious heart conditions like cardiomyopathy due to excess catecholamines. Early diagnosis is crucial for better outcomes in these rare but severe cardiovascular complications.
Area of Science:
- Cardiology
- Endocrinology
- Oncology
Background:
- Pheochromocytoma/paraganglioma (PPGL) are neuroendocrine tumors that secrete catecholamines.
- Excess catecholamines can lead to various cardiovascular syndromes, including cardiomyopathy.
- PPGL-induced cardiomyopathies affect up to 11% of patients, primarily linked to adrenal pheochromocytomas.
Purpose of the Study:
- To review the pathophysiology of catecholamine-induced cardiac damage.
- To describe the clinical presentation of PPGL-induced cardiomyopathies.
- To discuss current treatment strategies for these conditions.
Main Methods:
- Literature review of studies on PPGL and cardiomyopathy.
- Analysis of pathophysiological mechanisms of catecholamine effects on the heart.
- Synthesis of clinical data on presentation, diagnosis, and treatment.
Main Results:
- PPGL-induced cardiomyopathies present as acute (e.g., takotsubo) or chronic forms with distinct pathophysiologies.
- Acute stress causes myocardial stunning; chronic exposure leads to fibrosis, inflammation, necrosis, and dilated cardiomyopathy.
- Hypertension can be associated with hypertrophic cardiomyopathy in some cases.
- Chronic forms have a worse prognosis, with higher mortality and lower recovery rates.
Conclusions:
- PPGL-induced cardiomyopathies represent a significant cardiovascular risk associated with catecholamine excess.
- Understanding the different pathophysiological pathways is key to managing these conditions.
- Early diagnosis and intervention are essential for improving patient prognosis and outcomes.
More Related Videos
09:36Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
09:16Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
Published on: February 28, 2018
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Pathophysiology of Heart Failure